close

Biotechnology Valuation

Karl Keegan · ISBN 9780470511787
Biotechnology Valuation | Zookal Textbooks | Zookal Textbooks
Format:
Out of stock
$124.95  Save $28.99
$95.96
-
+
Publisher John Wiley & Sons (UK)
Author(s) Karl Keegan
Subtitle An Introductory Guide
Edition 1
Published 21st November 2008
Related course codes

An Introductory Guide


  • The first book to provide a simple and practical means of
    valuing biotech companies

  • The book begins with a short history of the biotechnology
    industry; this is important as although it is about 30 years old,
    the first company went public only in 1996, so it is possible to
    plot the course of investment waves and dips

  • It examines the European industry and its evolvement, and draws
    parallels between the similarities and differences between that and
    the US

  • Looks at the various companies which make up the biotech
    industry (therapeutic; life sciences; and the medical technology
    company) and gives tools for the investor to properly evaluate
    them


Praise for Biotechnology Valuation

"Keegan states that the valuation of Biotech companies is as
much an art as a science. This brief but comprehensive review of
the skills and knowledge required, not of just the financial market
and sentiment, but also of the technical attributes of a company
and the drug development and regulatory hurdles that must be
overcome, highlights the importance of the breadth of understanding
required. Biotech investing is not for the timid, but it can bring
substantial returns. Keegan's book, punctuated with his personal
experience and opinions, is a good place to start."

?Chris Blackwell, Chief Executive, Vectura Group
plc


"A user-friendly, yet thorough discussion of a notoriously
difficult topic. Dr Keegan's book is a fine resource for both
business types and academicians."

?Steve Winokur, Managing Director, CanaccordAdams


"A highly readable and comprehensive explanation of the
technical and commercial parameters that influence biotechnology
companies at all stages of development, providing clear context for
selection from the toolkit of valuation methodologies the author
recommends to assess company and product performance, or ascribe
value."

?Dr L.M. Allan, Director, Bioscience Enterprise
Programme, University of Cambridge


"A fabulous approach to a difficult topic."

?Deirdre Y. Gillespie, MD, President & CEO, La
Jolla Pharmaceutical Company

Translation missing: en.general.search.loading